Collegium Pharmaceutical is a specialty pharma company focused on pain management medicines, including abuse-deterrent opioid formulations. Its commercial portfolio has centered on products such as Xtampza ER and Nucynta for chronic and acute pain. The company targets physicians and patients who need controlled substances with features designed to deter misuse.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 188 | — | 12 | — |
| Q3 2025 | 209.4 | — | 31.5 | — |
| Q4 2025 | 205.4 | — | 17 | — |
| Q1 2026 | 193.5 | — | 14.5 | — |
| Q2 2026 | 199.9 | 6.3% | -15.1 | -225.6% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Fidus Investment Corporation (FDUS), River City Bank (RCBC), TaskUs, Inc. (TASK), Shore Bancshares, Inc. (SHBI), Transcat, Inc. (TRNS), Geron Corporation (GERN)